Does nebivolol prevent contrast-induced nephropathy in humans

Clinical Cardiology, 04/26/2012

Pretreatment with nebivolol is protective against nephrotoxic effects of contrast media.

Methods

  • The present study enrolled 120 patients scheduled for coronary angiography and ventriculography.
  • All patients were hydrated with intravenous isotonic saline.
  • The patients in group I received 600 mg N–acetylcysteine every 12 hours for 4 days.
  • The patients in group II received 5 mg nebivolol every 24 hours for 4 days.
  • The patients in group III were only hydrated.
  • The primary endpoint was the occurrence of CIN.
  • The secondary endpoint was the change in serum creatinine (Cr) levels at 2 days and 5 days after the contrast exposure.

Results

  • Nine (22.5%) patients in group I developed CIN, as did 8 patients (20.0%) in group II and 11 patients (27.5%) in group III (P = 0.72).
  • Changes in mean Cr level from baseline to day 2 were not statistically significant in all groups.
  • However, authors detected a statistically significant increase in mean Cr levels at day 5 compared with baseline levels in group I and group III (from 1.42 ± 0.13 to 1.52 ± 0.26, p2 = 0.02; and from 1.43 ± 0.14 to 1.55 ± 0.30, p2 = 0.01, respectively).
  • Although an increase was detected in mean Cr level from baseline to the 5–day Cr level in group II, this did not reach statistical significance (from 1.40 ± 0.12 to 1.48 ± 0.23, P = 0.06).

Print Article Summary Cat 2 CME Report